Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Rucaparib or physician's choice in metastatic prostate cancer - UROONCO Prostate Cancer
Rucaparib extends PFS in advanced prostate cancer
Clovis trots out Rubraca prostate cancer partial win
Current Oncology, Free Full-Text
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors - ScienceDirect
Optimizing Therapeutic Strategies in Castration-Resistant Prostate Cancer
Cancers, Free Full-Text
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer Treatment & Management: Approach Considerations, Localized Prostate Cancer, Management of Advanced and Metastatic Disease
PDF) The TRITON programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
de
por adulto (o preço varia de acordo com o tamanho do grupo)
